AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates21-12-2023
21-12-2023
Large cap pharma stock hits 52-week high after US FDA conducts inspection at unit's subsidiary; do you own?
Aurobindo Pharma20-12-2023
AUROBINDO PHARMA LTD. - 524804 - Classification Of US FDA Inspection At Unit IV Of APL Healthcare Ltd. - Receipt Of EIR Classifying The Facility As VAI
Unit IV of APL Healthcare Limited received Establishment Inspection Report classifying the facility as Voluntary Action Indicated (VAI).20-12-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor meet18-12-2023
AUROBINDO PHARMA LTD. - 524804 - Intimation Of Completion Of Acquisition Of Marketing And Manufacturing Related Authorisations From Viatris Inc. / Pfizer Inc.
Intimation of completion of acquisition of marketing and manufacturing related authorisations from Viatris Inc. / Pfizer Inc.15-12-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor group meeting on 13th December 2023.08-12-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of issue of letters of confirmation in lieu of duplicate share certificates08-12-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor meeting with AllianceBernstein on 6 December 202303-12-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates01-12-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Eugia Pharma, a wholly owned subsidiary of the Company, receives USFDA approval for Budesonide Inhalation Suspension30-11-2023